Ana Paula Costa1, Paulo César Giraldo2, Ricardo Ney Cobucci3, Márcia Lopes Consolaro4, Raquel Pantarotto Souza4, Luanda Barbara Canário5, Paula Renata Machado5, Rand Randall Martins6, Pedro Vieira Baptista7, José Eleutério Jr8, Ana Katherine Gonçalves1. 1. Postgraduate Program in Health Sciences, Federal University of Rio Grande do Norte, Natal, Brazil. 2. Department of Gynecology, and Obstetrics, State University of Campinas, Campinas, Brazil. 3. Postgraduate Program in Biotechnology, Potiguar University, Natal, Brazil. 4. Clinical Cytology and STD Laboratory, Department of Clinical Analysis and Biomedicine, State University of Maringá, Maringá, PR, Brazil. 5. Department of Clinical Analysis and Toxicology, Federal University of Rio Grande do Norte, Natal, Brazil. 6. Department of Pharmacy, Federal University of Rio Grande do Norte, Natal, Brazil. 7. Hospital Lusíadas Porto and Unidade de Tracto Genital Inferior, Serviço de Ginecologia e Obstetrícia, Centro Hospitalar de São João, Porto, Portugal. 8. Department of Female, Child and Adolescent Health, Federal University of Ceará, Fortaleza, Brazil.
Abstract
OBJECTIVE: The aim of the study was to describe the course of IgG/IgA immune response in women immunized with bivalent vaccine and in women non-vaccinated with HPV infection, as well as evaluating the cross-protection against non-vaccine HPV types. METHODS: Serum and cervical mucus samples were collected from infected and vaccinated women for HPV detection/genotyping and for detection of IgG/IgA anti-HPV/VLP (Virus-like Particles) by ELISA. RESULTS: The median absorbance detected in serum samples for anti-HPV-IgG antibodies was higher in vaccinated women when compared to HPV infected women (p <0.01), however, the median absorbance in cervical mucus samples for anti-HPV-IgA was higher in infected women when compared to vaccinated women (p <0.01). Additionally, our analyses also provided additional evidence for cross-protective efficacy of the HPV-16/18 vaccine against HPV-82, -6, -11, -13, -61, -72 and -74. CONCLUSION: The IgG antibodies were significantly more detected in the serum of vaccinated women, while the IgA was found in greater quantities in cervical samples from those infected by the virus. In addition, there is evidence that the bivalent vaccine provides cross-protection against other non-oncogenic viral subtypes.<br />.
OBJECTIVE: The aim of the study was to describe the course of IgG/IgA immune response in women immunized with bivalent vaccine and in women non-vaccinated with HPV infection, as well as evaluating the cross-protection against non-vaccine HPV types. METHODS: Serum and cervical mucus samples were collected from infected and vaccinated women for HPV detection/genotyping and for detection of IgG/IgA anti-HPV/VLP (Virus-like Particles) by ELISA. RESULTS: The median absorbance detected in serum samples for anti-HPV-IgG antibodies was higher in vaccinated women when compared to HPVinfectedwomen (p <0.01), however, the median absorbance in cervical mucus samples for anti-HPV-IgA was higher in infectedwomen when compared to vaccinated women (p <0.01). Additionally, our analyses also provided additional evidence for cross-protective efficacy of the HPV-16/18 vaccine against HPV-82, -6, -11, -13, -61, -72 and -74. CONCLUSION: The IgG antibodies were significantly more detected in the serum of vaccinated women, while the IgA was found in greater quantities in cervical samples from those infected by the virus. In addition, there is evidence that the bivalent vaccine provides cross-protection against other non-oncogenic viral subtypes.<br />.
Entities:
Keywords:
Cross Protection; HPV; Immunoglobulin G; Vaccine; immunoglobulin A
Authors: Troy J Kemp; Allan Hildesheim; Mahboobeh Safaeian; Joseph G Dauner; Yuanji Pan; Carolina Porras; John T Schiller; Douglas R Lowy; Rolando Herrero; Ligia A Pinto Journal: Vaccine Date: 2011-01-15 Impact factor: 3.641
Authors: Xavier Castellsagué; Paulo Naud; Song-Nan Chow; Cosette M Wheeler; Maria Julieta V Germar; Matti Lehtinen; Jorma Paavonen; Unnop Jaisamrarn; Suzanne M Garland; Jorge Salmerón; Dan Apter; Henry Kitchener; Julio C Teixeira; S Rachel Skinner; Genara Limson; Anne Szarewski; Barbara Romanowski; Fred Y Aoki; Tino F Schwarz; Willy A J Poppe; F Xavier Bosch; Newton S de Carvalho; Klaus Peters; Wiebren A A Tjalma; Mahboobeh Safaeian; Alice Raillard; Dominique Descamps; Frank Struyf; Gary Dubin; Dominique Rosillon; Laurence Baril Journal: J Infect Dis Date: 2014-03-08 Impact factor: 5.226
Authors: Barbara Romanowski; Tino F Schwarz; Linda Ferguson; Klaus Peters; Marc Dionne; Ulrich Behre; Karin Schulze; Peter Hillemanns; Pemmaraju Suryakiran; Florence Thomas; Frank Struyf Journal: Hum Vaccin Immunother Date: 2015-07-15 Impact factor: 3.452
Authors: Petra J Woestenberg; Audrey J King; Birgit H B van Benthem; Robine Donken; Suzan Leussink; Fiona R M van der Klis; Hester E de Melker; Marianne A B van der Sande; Christian J P A Hoebe; Johannes A Bogaards Journal: J Infect Dis Date: 2018-01-04 Impact factor: 5.226
Authors: Jade Pattyn; Severien Van Keer; Wiebren Tjalma; Veerle Matheeussen; Pierre Van Damme; Alex Vorsters Journal: Papillomavirus Res Date: 2019-09-05